Zabdeno (monovalent ebola virus vaccine) / J&J  >>  Phase 3
Welcome,         Profile    Billing    Logout  

9 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zabdeno (monovalent ebola virus vaccine) / J&J
NCT02543268: A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

Completed
3
329
US
Ad26.ZEBOV-Batch #1, Ad26.ZEBOV-Batch #2, Ad26.ZEBOV-Batch #3, MVA-BN-Filo, Placebo
Crucell Holland BV
Healthy
01/16
07/16
NCT02543567: A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

Completed
3
525
US
Ad26.ZEBOV 5*10^10 viral particles (vp), Ad26.ZEBOV 2*10^10 (vp), Ad26.ZEBOV 0.8*10^10 (vp), MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.], MVA-BN-Filo 5*10^7 Inf. U., Placebo
Janssen Vaccines & Prevention B.V.
Healthy
06/16
11/16
EBOVAC-Salone, NCT02509494 / 2019-000691-42: Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo

Completed
3
1023
RoW
Ad26.ZEBOV, MVA-BN-Filo, MenACWY, Placebo
Janssen Vaccines & Prevention B.V., London School of Hygiene and Tropical Medicine (LSHTM), Ministry of Health and Sanitation of Sierra Leone, College of Medicine and Allied Health Sciences (COMAHS), University of Oxford, Institut National de la Santé Et de la Recherche Médicale, France, Grameen Foundation, World Vision of Ireland
Ebola Virus Disease
06/19
07/19
NCT02661464: Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo

Terminated
3
677
Europe, US, RoW
Ad26.ZEBOV, MVA-BN-Filo
Janssen Vaccines & Prevention B.V., Bavarian Nordic GmbH
Hemorrhagic Fever, Ebola
12/21
12/21
NCT04152486: Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC

Active, not recruiting
3
20426
RoW
Ad26.ZEBOV, MVA-BN-Filo vaccine
London School of Hygiene and Tropical Medicine, Epicentre, Ministère de la Santé de la RDC, Médecins Sans Frontières, France, Coalition for Epidemic Preparedness Innovations, Janssen Vaccines & Prevention B.V., Public Health England
Ebola Virus Disease
01/22
02/22
NCT04228783: A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants

Completed
3
974
US
Ad26.ZEBOV, MVA-BN-Filo, Placebo
Janssen Vaccines & Prevention B.V.
Ebola
04/22
04/22
NCT02967003 / 2015-004139-11: Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo

Recruiting
3
5500
US, Europe, RoW
Ad26.ZEBOV, MVA-BN-Filo
Janssen Vaccines & Prevention B.V., Bavarian Nordic GmbH
Hemorrhagic Fever, Ebola
05/22
05/22
INGABO, NCT04556526: A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women

Completed
3
4031
RoW
Ad26.ZEBOV, MVA-BN-Filo
Janssen Vaccines & Prevention B.V., Center for Family Health Research (CFHR), Coalition for Epidemic Preparedness Innovations, Emory University
Healthy
03/23
03/23
EBO-BOOST, NCT06126822: Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination With the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRC

Not yet recruiting
3
624
RoW
Zabdeno® booster, Ervebo® booster
Institute of Tropical Medicine, Belgium, Institut National pour la Recherche Biomedicale (INRB)
Ebola Virus Disease
10/25
10/26

Download Options